PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025)
PRF Technologies' (PRFX) quarterly Total Non-Current Liabilities came in at $267000.0 in Q4 2025, up 3.09% YoY from $259000.0 in Q4 2024, and up 1.52% on a QoQ basis from $263000.0 in Q2 2025.
PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has 7 years of Total Non-Current Liabilities data on file, last reported at $267000.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3.09% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267000.0 (up 3.09% YoY) and the FY2025 annual result came in at $267000.0, up 3.09% from the prior year.
- Total Non-Current Liabilities rose to $267000.0 in Q4 2025, from $263000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 million in Q3 2023 to a low of $213000.0 in Q1 2021.
- A 5-year average of $412000.0 and a median of $259000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 367.08% — and 2024, when it tumbled 77.18%.
- Tracing PRFX's Total Non-Current Liabilities over 5 years: stood at $234000.0 in 2021, then advanced by 3.85% to $243000.0 in 2022, then surged by 367.08% to $1.1 million in 2023, then plunged by 77.18% to $259000.0 in 2024, then gained by 3.09% to $267000.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $267000.0 (Q4 2025), $263000.0 (Q2 2025), and $259000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Dec 31, 2024 | 259,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | 245,000.00 |
| Dec 31, 2022 | 243,000.00 |
| Jun 30, 2022 | 549,000.00 |
| Mar 31, 2022 | 236,000.00 |
| Dec 31, 2021 | 234,000.00 |
| Jun 30, 2021 | 613,000.00 |
| Mar 31, 2021 | 213,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | -1.07 Mn |
| Jun 30, 2020 | 1.51 Mn |
| Mar 31, 2020 | -802,000.00 |
| Dec 31, 2019 | 447,000.00 |